| 2004 | 2007 | |||||||
---|---|---|---|---|---|---|---|---|---|
 | Liberals | Conservatives | Bloc Quebecois | NDP | Liberals | Conservatives | Bloc Quebecois | NDP | Independent |
 | (n = 25593) | (n = 7864) | (n = 5467) | (n = 8159) | (n = 5474) | (n = 4935) | (n = 2013) | (n = 3168) | (n = 1352) |
Equity | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Aid | 3% | 8% | 6% | 6% | 33% | 11% | 22% | 2% | 9% |
List of Countries | 18% | 14% | 10% | 11% | 1% | 2% | 0% | 3% | 0% |
List of Medicines | 12% | 14% | 8% | 16% | 0% | 7% | 19% | 4% | 0% |
Equal Opportunity to supply | 2% | 0% | 6% | 0% | 0% | 0% | 0% | 0% | 0% |
Security | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Drug Affordability | 6% | 1% | 0% | 7% | 11% | 2% | 10% | 6% | 0% |
Development | 2% | 5% | 4% | 4% | 6% | 9% | 24% | 7% | 24% |
Domestic Economy | 0% | 0% | 0% | 0% | 0% | 1% | 0% | 0% | 0% |
Human Rights | 1% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Innovation | 2% | 3% | 0% | 0% | 0% | 2% | 0% | 0% | 4% |
Quality and Safety | 1% | 1% | 0% | 2% | 0% | 2% | 0% | 0% | 0% |
Liberty | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Intellectual Property | 36% | 22% | 20% | 25% | 17% | 29% | 20% | 11% | 7% |
Developing Country Pressure | 0% | 0% | 0% | 0% | 2% | 0% | 0% | 4% | 0% |
Right of Refusal | 10% | 9% | 2% | 8% | 0% | 0% | 0% | 0% | 0% |
WTO or TRIPS | 15% | 5% | 8% | 10% | 11% | 2% | 6% | 4% | 20% |
Efficiency | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Diversion | 7% | 5% | 14% | 1% | 1% | 0% | 10% | 0% | 14% |
Litigation | 1% | 4% | 7% | 2% | 1% | 3% | 0% | 0% | 0% |
Market Competition | 4% | 0% | 0% | 0% | 3% | 5% | 0% | 0% | 0% |
Procurement | 1% | 3% | 1% | 4% | 8% | 0% | 5% | 0% | 3% |
Profit and ROI | 7% | 0% | 0% | 3% | 5% | 6% | 2% | 4% | 0% |
Eligible Importers | 3% | 4% | 11% | 3% | 0% | 1% | 0% | 0% | 0% |
CAMR Outcomes and Uptake | 0% | 0% | 0% | 0% | 21% | 16% | 33% | 49% | 41% |